Palliative (low dose) radiation plus Veyonda is proving to be an eye-opener. The strong reduction of PSA levels in patients who achieved partial abscopal responses, months after treatment finished, suggests that an abscopal response induced by Veyonda is not only durable; but seems to increase over time - with no side effects.
Ann: NOX to Present Clinical Data at COSA Annual Meeting, page-2
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $4.773K | 48.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20574 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 38542 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
